SCHEMBL2065925

SCHEMBL2065925

CCN(CC)C(CCl)Oc1ccc(Cl)cc1-c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGDR2 Q9Y5Y4 3/20 0.46
▸ TSHR P16473 1/20 0.38
▸ SLC6A9 P48067 2/20 0.37
▸ FFAR1 O14842 1/20 0.36
▸ FFAR4 Q5NUL3 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ NPSR1 Q6W5P4 1/20 0.35
▸ L3MBTL1 Q9Y468 2/20 0.35
▸ MAPT P10636 1/20 0.34
▸ PKM P14618 1/20 0.34
▸ CTSA P10619 3/20 0.34
▸ SLC6A2 P23975 1/20 0.34
▸ SLC6A4 P31645 1/20 0.34
▸ SLC6A3 Q01959 1/20 0.34
▸ PPARA Q07869 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ PTGER1 P34995 1/20 0.34
▸ NLRP3 Q96P20 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2065926 0.76 PTGDR2 (0.46) PTGDR2TSHRSLC6A9FFAR1FFAR4
SCHEMBL2067287 0.76 PTGDR2 (0.51) PTGDR2SLC6A9FFAR1FFAR4CTSA
SCHEMBL16150998 0.75 PTGDR2 (0.53) PTGDR2TSHRSLC6A9ALDH1A1SLC6A4
SCHEMBL11623453 0.74 PTGDR2 (0.50) PTGDR2TSHRSLC6A9L3MBTL1MAPT
SCHEMBL11619019 0.71 PTGDR2 (0.56) PTGDR2SLC6A9FFAR1FFAR4PTGER1
SCHEMBL2067290 0.71 PTGDR2 (0.51) PTGDR2SLC6A9FFAR1FFAR4SLC6A2
SCHEMBL29634149 0.70 PTGDR2 (0.57) PTGDR2TSHRKDM4EALDH1A1NPSR1
SCHEMBL3759371 0.70 PTGDR2 (0.57) PTGDR2TSHRKDM4EALDH1A1NPSR1
SCHEMBL29772176 0.69 PTGDR2 (0.60) PTGDR2SLC6A9FFAR1FFAR4KDM4E
SCHEMBL27524115 0.69 PTGDR2 (0.60) PTGDR2SLC6A9FFAR1FFAR4KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130303437-A1 ANTIMICROBIAL THERAPY FOR BACTERIAL INFECTIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2013-11-14 — — US claimed
US-8507551-B2 Antimicrobial therapy for bacterial infections THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-08-13 — — US claimed
US-20090042976-A1 Antimicrobial therapy for bacterial infections THE REGENTS OF THE UNIVERSITY OF CALIFORNIS (US) 2009-02-12 — — US claimed
US-8778913-B2 Antimicrobial compositions for treating microbial infections THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2014-07-15 — — US disclosed
US-20140154302-A1 ANTIMICROBIAL COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS THE UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN (US) 2014-06-05 — — US disclosed
US-20130303437-A1 ANTIMICROBIAL THERAPY FOR BACTERIAL INFECTIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2013-11-14 — — US disclosed
US-8507551-B2 Antimicrobial therapy for bacterial infections THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-08-13 — — US disclosed
US-8148352-B2 Antimicrobial therapy for bacterial infections THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-04-03 — — US disclosed
US-20090306021-A1 ANTIMICROBIAL THERAPY FOR BACTERIAL INFECTIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2009-12-10 — — US disclosed
EP-1881760-A4 ANTIMICROBIAL THERAPY FOR BACTERIAL INFECTIONS UNIV CALIFORNIA (US) 2009-03-25 — — EP disclosed
US-20090042976-A1 Antimicrobial therapy for bacterial infections THE REGENTS OF THE UNIVERSITY OF CALIFORNIS (US) 2009-02-12 — — US disclosed
EP-1881760-A2 ANTIMICROBIAL THERAPY FOR BACTERIAL INFECTIONS The Regents of the University of California (US) 2008-01-30 — — EP disclosed
WO-2007075186-A2 ANTIMICROBIAL THERAPY FOR BACTERIAL INFECTIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-07-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306021-A1 ANTIMICROBIAL THERAPY FOR BACTERIAL INFECTIONS SERPINB1, CUTA, SRRT PTGDR2 3898/4885TSHR 3670/4885SLC6A9 4029/4885
US-20140154302-A1 ANTIMICROBIAL COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS MPO, CUTA, STING1 PTGDR2 3623/4885TSHR 4190/4885SLC6A9 4690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback